Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yoji Ino is active.

Publication


Featured researches published by Yoji Ino.


Bioorganic & Medicinal Chemistry Letters | 2014

Synthetic studies on mitotic kinesin Eg5 inhibitors: Synthesis and structure–activity relationships of novel 2,4,5-substituted-1,3,4-thiadiazoline derivatives

Junichiro Yamamoto; Nobuyoshi Amishiro; Kazuhiko Kato; Yoshihisa Ohta; Yoji Ino; Mitsuharu Araki; Tetsuya Tsujita; Seiho Okamoto; Takeshi Takahashi; Hideaki Kusaka; Shiro Akinaga; Yoshinori Yamashita; Ryuichiro Nakai; Chikara Murakata

The 2,4,5-substituted-1,3,4-thiadiazoline derivative 1a has been identified as a new class of mitotic kinesin Eg5 inhibitor. With the aim of enhancement of the mitotic phase accumulation activity, structure optimization of side chains at the 2-, 4-, and 5-positions of the 1,3,4-thiadiazoline ring of 1a was performed. The introduction of sulfonylamino group at the side chain at the 5-position and bulky acyl group at the 2- and 4-position contributed to a significant increase in the mitotic phase accumulation activity and Eg5 inhibitory activity. As a result, a series of optically active compounds exhibited an increased antitumor activity in a human ovarian cancer xenograft mouse model that was induced by oral administration.


Archive | 2006

Mitotic kinesin inhibitor

Yoji Ino


Archive | 2004

M-Stage-Kinesin-Inhibitor

Chikara Murakata; Yoshinori Yamashita; Ryuichiro Nakai; Kazuhito Akasaka; Yoji Ino; Kazuhiko Kato; Yushi Kitamura


Archive | 2001

Estra-1,3,5(10)-triene derivatives

Yoji Ino; Nobuyoshi Amishiro; Mayumi Miyata; Tsutomu Agatsuma; Kozue Muramatsu; Takeshi Takahashi; Shiro Akinaga; Chikara Murakata


Archive | 2002

Aryl sulfamate derivatives

Yoji Ino; Nobuyoshi Amishiro; Kozue Muramatsu; Yukimasa Shiotsu; Chikara Murakata


Archive | 2006

Agent for treatment of solid tumor

Chikara Murakata; Kazuhiko Kato; Junichiro Yamamoto; Ryuichiro Nakai; Seiho Okamoto; Yoji Ino; Yushi Kitamura; Toshikazu Saitoh; Takeshi Katsuhira


Archive | 2004

Thiadiazoline-1-oxide derivative

Chikara Murakata; Yoji Ino; Kazuhiko Kato; Junichiro Yamamoto; Ryuichiro Nakai; Masahiro Hoshikawa; Koji Suzuki


Archive | 2006

Therapeutic agent for solid tumor

Chikara Murakata; Kazuhiko Kato; Junichiro Yamamoto; Ryuichiro Nakai; Seiho Okamoto; Yoji Ino; Yushi Kitamura; Toshikazu Saitoh; Takeshi Katsuhira


Archive | 2001

Treating agent for rheumatoid arthritis

Kazuto Akasaka; Nobuyoshi Amishiro; Yoshi Honma; Michiaki Ichimura; Yoji Ino; Tsutomu Muragata; Motoo Yamazaki; 洋二 井野; 基生 山▲崎▼; 通朗 市村; 好 本間; 力 村形; 宣善 網城; 一人 赤坂


Archive | 2004

Inihibiteur de kinesine de stade m

Chikara Murakata; Yoshinori Yamashita; Ryuichiro Nakai; Kazuto Akasaka; Yoji Ino; Kazuhiko Kato; Yuji Kitamura

Collaboration


Dive into the Yoji Ino's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge